Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.

BMC cancer - 28 Jul 2018

Kim In Ae, Lee Jong Sik, Kim Hee Joung, Kim Wan Seop, Lee Kye Young

Abstract excerpt

BACKGROUND: Although lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations is common in never smokers, one-third of the patients are ever-smokers. We aimed to investigate the effect of cumulative smoking dose(CSD) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS), in patients with EGFR-mutated lung adenocarcinoma receiving EGFR-tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Smoking

Source

Open in PubMed Open full text

Identifiers

PMID: 30055587
DOI: 10.1186/s12885-018-4691-0
PMCID: PMC6064083

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.PMID 30055587Read ↗

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Semantic proximity Read ↗

Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.Semantic proximity Read ↗

Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.Semantic proximity Read ↗

Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations.Semantic proximity Read ↗

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Lung cancer in never smokers: a review.Semantic proximity Read ↗

Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.Semantic proximity Read ↗

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.Semantic proximity Read ↗

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.Semantic proximity Read ↗

Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.Semantic proximity Read ↗

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.Semantic proximity Read ↗

Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.